# Radiotherapy With or Without Concurrent Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-03

> **NCT03328234** · PHASE3 · UNKNOWN · sponsor: **Chinese Academy of Medical Sciences** · enrollment: 2 (estimated)

## Conditions studied

- IMRT With or Without Concurrent Chemotherapy for Esophageal Cancer

## Interventions

- **RADIATION:** SIB-IMRT
- **DRUG:** Paclitaxel
- **DRUG:** Platinum-Based Drug
- **DRUG:** Paclitaxel
- **DRUG:** Platinum-Based Drug
- **OTHER:** Involved Field Irradiation (IFI)

## Key facts

- **NCT ID:** NCT03328234
- **Lead sponsor:** Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-09-01
- **Primary completion:** 2021-08-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 2 (ESTIMATED)
- **Last updated:** 2019-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03328234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03328234, "Radiotherapy With or Without Concurrent Chemotherapy for Extensive Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-03". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03328234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*